Peptides›Blend, Metabolic›Retatrutide + Cagrilintide (Blend)

Retatrutide + Cagrilintide (Blend)

/ Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus cagrilintide (long-acting amylin analog)

TIER 2 · TranslationalN = 0 · TESTING PENDING

ALIAS · SA-3R/SA-4C · Triple-agonist + amylin analog blend

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus cagrilintide (long-acting amylin analog)CATEGORY · Blend, Metabolic

Tier 2 by component evidence. Both molecules independently have Phase 2 or Phase 3 obesity-trial data. Eli Lilly is actively developing the combination commercially (TRIUMPH program for retatrutide + non-cagrilintide co-agents); the specific retatrutide + cagrilintide combination is discussed in obesity literature but no dedicated published RCT exists as of early 2026.

§ B · Mechanism of action

Convergent metabolic appetite-suppression and energy-expenditure pharmacology. Retatrutide engages three receptors (GLP-1, GIP, glucagon) for synergistic incretin and thermogenic effect. Cagrilintide is a long-acting acylated amylin analog producing satiety and slowed gastric emptying through amylin receptor signalling. The combined incretin + amylin-analog approach is the rationale behind CagriSema (cagrilintide + semaglutide), which has Phase 3 data — the retatrutide + cagrilintide combination has the same scientific basis but lacks dedicated trials.

§ C · Human clinical evidence

No published RCT of the specific retatrutide + cagrilintide combination. Component evidence: retatrutide Phase 2 obesity data (Jastreboff 2023, NEJM) showed up to 24% weight loss at 48 weeks; cagrilintide Phase 2 obesity data (combined with semaglutide as CagriSema) reported significant weight loss versus monotherapy.

§ D · Primary literature

PubMed37366315Jastreboff AM et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial · The New England Journal of Medicine · human-phase-2Retatrutide produced 24.2% weight loss at 48 weeks (highest dose 12 mg weekly) versus 2.1% placebo; established proof-of-concept for triple GLP-1/GIP/glucagon receptor agonism in obesity.Limitations: Phase 2; 48-week duration; nausea/vomiting dose-limiting in higher-dose arms.2023

§ F · Safety signal

No combined safety database. Component-level GI adverse events (nausea, vomiting) are dose-limiting for both classes individually; combination tolerability is inferred but not established.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Vendor sale of retatrutide and cagrilintide as separately compounded research peptides predates clinical-trial validation of the specific combination. Editors should treat the 'protocol' as not supported by RCT evidence.